Latest guidelines on blood pressure
Reading File
Searching the Web
2025 2026 blood pressure hypertension guidelines ACC AHA ESC
Searching PubMed
"hypertension" AND "guidelines"
Reading Article
PMID: 40811516
Reading Article
PMID: 39210715
Reading Web Page
https://www.cardi-oh.org/resources/current-57--2025-accaha-g…
Here is a comprehensive, up-to-date summary of the current blood pressure guidelines:
Blood Pressure Guidelines: 2025 ACC/AHA & 2024 ESC
The Two Major Guidelines
There are now two current guidelines to know:
- 2025 AHA/ACC Guideline (PMID: 40811516) - published October 2025, replaces the 2017 guideline. Endorsed by 13 professional societies.
- 2024 ESC Guideline (PMID: 39210715) - published October 2024, replaces the 2018 ESC guideline.
BP Classification
| Category | ACC/AHA 2025 (SBP/DBP) | ESC 2024 (SBP/DBP) |
|---|---|---|
| Normal | <120/<80 | <120/<80 |
| Elevated / High-normal | 120-129 / <80 | 120-129 / 80-84 |
| Stage 1 / Grade 1 | 130-139 / 80-89 | 140-159 / 90-99 |
| Stage 2 / Grade 2 | ≥140 / ≥90 | 160-179 / 100-109 |
| Stage 3 / Grade 3 | - | ≥180 / ≥110 |
| Hypertensive crisis | ≥180/120 + organ damage | same concept |
Note: The ACC/AHA still uses its 130/80 threshold for defining hypertension (from 2017), while the ESC uses 140/90 as its diagnostic threshold. Many individuals labeled "Stage 1 hypertensive" in the US are classified as "elevated" or "high-normal" in Europe.
Treatment Targets
2025 ACC/AHA:
- Universal target: <130/80 mmHg for all adults
- Encourage SBP <120 mmHg when feasible to maximize CVD risk reduction
- Exceptions: institutionalized/nursing home patients, limited life expectancy, pregnancy
2024 ESC:
- Primary target: <140/80 mmHg for most patients
- Tighter targets by age (if well tolerated):
- Age 18-64: 120-129 / 70-79 mmHg
- Age 65-79: 130-139 mmHg (systolic)
- Age ≥80 or frail: 140-150 mmHg (systolic)
When to Start Drug Therapy
2025 ACC/AHA:
- Start immediately if BP ≥140/90 mmHg (regardless of risk)
- Start immediately if BP ≥130/80 mmHg with: established CVD, prior stroke, diabetes, CKD, or 10-year CVD risk ≥7.5% (using the new PREVENT™ equation, which replaces the Pooled Cohort Equation)
- For lower-risk adults with BP 130-139/80-89: start drugs if BP persists after 3-6 months of lifestyle therapy
2024 ESC:
- Start immediately in Grade 2-3 hypertension (≥160/100) and in high-risk Grade 1
- 3-6 month lifestyle trial before drugs in low-risk Grade 1 (<150/95)
- High-normal BP (130-139/80-89): drugs only if established coronary artery disease
First-Line Drug Therapy
All three major guidelines agree on the same four first-line drug classes:
- ACE inhibitors (ACEi)
- Angiotensin receptor blockers (ARBs)
- Long-acting dihydropyridine calcium channel blockers (DHP-CCB)
- Thiazide/thiazide-like diuretics
Key 2025 ACC/AHA updates:
- First-line selection is now race-neutral - prior race-based recommendations (e.g., preferring CCBs in Black patients) have been removed. Evidence showed race has limited predictive value for antihypertensive response.
- Stage 2 hypertension (≥140/90): prefer single-pill dual-class fixed-dose combinations to improve adherence and speed BP control.
Key New Additions in 2025 ACC/AHA
| Change | Details |
|---|---|
| Risk calculator | PREVENT™ replaces the Pooled Cohort Equation |
| Race neutrality | No race-based drug selection |
| Dementia prevention | Intensive BP lowering (target <130 mmHg) now shown to reduce risk of cognitive decline and dementia |
| Combination pills | Preferred upfront for Stage 2 |
| Living document | Designated as a "living guideline" with planned ongoing updates |
| Renal denervation (RDN) | Incorporated for selected patients with resistant hypertension (SBP 140-180, DBP ≥90, on ≥4 drugs including an MRA) |
Resistant Hypertension
All guidelines define resistant hypertension as failure to reach target BP on ≥3 agents (including a diuretic) at optimal doses. Management across all guidelines:
- Confirm with ambulatory (ABPM) or home BP monitoring
- Exclude pseudo-resistance (poor adherence, white coat effect, therapeutic inertia)
- Rule out secondary causes (especially primary aldosteronism)
- Optimize diuretic, add spironolactone (MRA) as next step
- Renal denervation (FDA-approved 2023): now Class IIb in all three guidelines for carefully selected patients
Lifestyle Modifications (All Guidelines)
These remain foundational regardless of drug therapy:
- Weight loss (target BMI <25)
- DASH or Mediterranean diet, low sodium (<1.5 g/day per AHA)
- Physical activity - 150 min/week moderate aerobic exercise
- Alcohol reduction - ≤1 drink/day for women, ≤2 for men
- Smoking cessation
- Stress reduction
Sources:
- 2025 ACC/AHA Hypertension Guideline (Circulation 2025;152:e114-e218; PMID 40811516)
- 2024 ESC Hypertension Guideline (Eur Heart J 2024; PMID 39210715)
- Trans-Atlantic Comparison of 2025 AHA/ACC vs ESC/ESH
Diff between stress and urge incontinence
Reading File
Finding Sources
Searching the Web
stress vs urge urinary incontinence pathophysiology diagnosis treatment difference
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Excellent textbook content. I now have all the clinical detail needed for a thorough comparison. Here is the full answer:
Stress vs. Urge Urinary Incontinence
Definition & Core Mechanism
| Stress Incontinence (SUI) | Urge Incontinence (UUI) | |
|---|---|---|
| ICS Definition | Involuntary urine leakage on effort, exertion, coughing, or sneezing | Involuntary urine leakage accompanied or immediately preceded by a sudden urge to void |
| Core problem | Failure of the urethral sphincter/pelvic floor to resist increased abdominal pressure | Involuntary detrusor (bladder muscle) contraction - "overactive bladder" (OAB) |
| Underlying lesion | Weak pelvic floor muscles, bladder neck hypermobility, or intrinsic sphincter deficiency | Detrusor overactivity (idiopathic, neurogenic, or obstructive) |
Pathophysiology
Stress Incontinence
During normal continence, a rise in abdominal pressure (cough, sneeze, lifting) is matched by a reflexive rise in urethral closure pressure. In SUI, this fails because of:
- Bladder neck/urethral hypermobility - pelvic floor laxity causes the vesicourethral segment to descend and lose its sphincteric geometry
- Intrinsic sphincter deficiency (ISD) - the sphincter itself is structurally weak; the bladder neck is open at rest with minimal descent under stress (seen after repeated pelvic surgeries)
Both mechanisms often coexist. The pelvic floor musculature acts like a hammock to support the urethra; its laxity dissipates all three continence forces.
Urge Incontinence
The detrusor muscle contracts involuntarily, generating bladder pressure that overcomes urethral resistance. Histologically, detrusor overactivity is associated with widened intercellular spaces, abnormal muscle cell junctions ("protrusion junctions"), and altered cell-coupling that shifts from mechanical to electrical mechanisms - triggering involuntary contractions. Contributing causes include:
- Central inhibitory pathway lesions (stroke, Parkinson's, dementia)
- Bladder outlet obstruction (e.g., BPH in men)
- Bladder irritants (infection, stones, carcinoma)
- Age-related smooth muscle changes, pelvic irradiation
- Often idiopathic
Clinical Features
| Feature | Stress Incontinence | Urge Incontinence |
|---|---|---|
| Trigger | Cough, sneeze, laugh, lift, exercise | Sudden urge; may be triggered by running water, cold, key-in-door |
| Warning time | None - leakage is simultaneous with exertion | Brief warning but unable to defer voiding |
| Volume leaked | Usually small | Moderate to large; often complete bladder emptying |
| Urgency | Absent | Hallmark feature |
| Frequency/nocturia | Usually absent | Common |
| Nocturia | Uncommon | Common |
| Postvoid residual | Normal | Usually normal (elevated if detrusor overactivity + impaired contractility coexist) |
| Who is affected | Predominantly women; post-vaginal delivery, post-menopausal, obese | Both sexes; more common with aging, post-stroke, BPH in men |
Risk Factors
| Stress Incontinence | Urge Incontinence |
|---|---|
| Vaginal deliveries / obstructed labor | Advancing age |
| Menopause (estrogen loss) | Neurological disease (stroke, MS, Parkinson's) |
| Obesity | BPH / bladder outlet obstruction |
| Prior pelvic/urethral surgery | Bladder stones, infection, carcinoma |
| Chronic cough | Caffeine, alcohol use |
| Connective tissue disorders | Idiopathic (majority of cases) |
Diagnosis
- History alone is often sufficient to classify. The validated 3-Incontinence Questions (3IQ) tool asks whether leakage occurs with physical activity, with urgency, or both - and classifies as stress-only, urge-only, or mixed.
- Physical exam: Cough stress test in lithotomy or standing position - simultaneous leakage with cough = stress incontinence. Delayed leakage (detrusor contracts after cough) = detrusor overactivity.
- Urinalysis + post-void residual: Rule out UTI and overflow incontinence in all patients.
- Urodynamics: Reserved for complex/refractory cases, prior failed surgery, or mixed symptoms. Demonstrates uninhibited detrusor contractions (UUI) vs. urodynamic stress incontinence.
- Cystoscopy: If hematuria, recurrent infection, or suspected malignancy.
Management
Stress Incontinence
| Approach | Options |
|---|---|
| Conservative (1st line) | Pelvic floor muscle training (Kegel exercises); weight loss; caffeine/fluid management |
| Mechanical | Pessary (incontinence ring or dish) for bladder neck support |
| Pharmacological | Duloxetine (SNRI, increases urethral sphincter tone via pudendal nerve) - used in some countries; topical estrogen in post-menopausal women |
| Surgical (gold standard) | Mid-urethral sling (MUS) - retropubic (TVT) or transobturator (TOT); colposuspension (Burch); bulking agents for ISD |
Urge Incontinence / OAB
| Approach | Options |
|---|---|
| Conservative (1st line) | Bladder training (timed voiding, urge suppression techniques); pelvic floor training; fluid/caffeine restriction |
| Pharmacological | Antimuscarinics (oxybutynin, solifenacin, tolterodine, darifenacin) - block detrusor M3 receptors; Beta-3 agonists (mirabegron, vibegron) - relax detrusor, fewer anticholinergic side effects; preferred in elderly |
| 3rd line | Intradetrusor botulinum toxin A injections; Sacral neuromodulation (InterStim); percutaneous tibial nerve stimulation (PTNS) |
Mixed Incontinence
About 30-40% of women have features of both. The urge component is usually more bothersome. Treat the predominant type first. The 3IQ tool classifies this as "about equally with physical activity and sense of urgency."
Sources:
- Smith and Tanagho's General Urology, 19th ed., p. 513
- Textbook of Family Medicine, 9th ed.
- Goldman-Cecil Medicine, p. 1325
- Harrison's Principles of Internal Medicine, 22nd ed. (2025), p. 3933-3934
This is a shared conversation. Sign in to Orris to start your own chat.